关注
Heather Jane Chalfin
Heather Jane Chalfin
Urology Resident, Johns Hopkins Hospital
在 jhmi.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors
AB Apolo, R Nadal, DM Girardi, SA Niglio, L Ley, LM Cordes, ...
Journal of Clinical Oncology 38 (31), 3672-3684, 2020
1092020
Impact of surgical margin status on prostate‐cancer‐specific mortality
HJ Chalfin, M Dinizo, BJ Trock, Z Feng, AW Partin, PC Walsh, ...
BJU international 110 (11), 1684-1689, 2012
1042012
Hospital charges and length of stay following radical cystectomy in the enhanced recovery after surgery era
A Semerjian, N Milbar, M Kates, MA Gorin, HD Patel, HJ Chalfin, ...
Urology 111, 86-91, 2018
772018
The relationship between the extent of extraprostatic extension and survival following radical prostatectomy
BC Jeong, HJ Chalfin, SB Lee, Z Feng, JI Epstein, BJ Trock, AW Partin, ...
European urology 67 (2), 342-346, 2015
672015
New prostate cancer grading system predicts long-term survival following surgery for Gleason score 8–10 prostate cancer
WS Ham, HJ Chalfin, Z Feng, BJ Trock, JI Epstein, C Cheung, ...
European urology 71 (6), 907-912, 2017
612017
Obesity and long-term survival after radical prostatectomy
HJ Chalfin, SB Lee, BC Jeong, SJ Freedland, H Alai, Z Feng, BJ Trock, ...
The Journal of urology 192 (4), 1100-1104, 2014
532014
Variability in medicare utilization and payment among urologists
JS Ko, H Chalfin, BJ Trock, Z Feng, E Humphreys, SW Park, HB Carter, ...
Urology 85 (5), 1045-1051, 2015
482015
Blood transfusion is associated with increased perioperative morbidity and adverse oncologic outcomes in bladder cancer patients receiving neoadjuvant chemotherapy and radical …
HJ Chalfin, JJ Liu, N Gandhi, Z Feng, D Johnson, GJ Netto, CG Drake, ...
Annals of surgical oncology 23, 2715-2722, 2016
412016
Allogeneic versus autologous blood transfusion and survival after radical prostatectomy (CME)
HJ Chalfin, SM Frank, Z Feng, BJ Trock, CG Drake, AW Partin, ...
Transfusion 54 (9), 2168-2174, 2014
392014
Circulating tumor cell and circulating tumor DNA assays reveal complementary information for patients with metastatic urothelial cancer
HJ Chalfin, SA Glavaris, MA Gorin, MR Kates, MH Fong, L Dong, ...
European urology oncology 4 (2), 310-314, 2021
352021
Circulating tumor cell subtypes and T-cell populations as prognostic biomarkers to combination immunotherapy in patients with metastatic genitourinary cancer
HJ Chalfin, T Pramparo, A Mortazavi, SA Niglio, JD Schonhoft, ...
Clinical Cancer Research 27 (5), 1391-1398, 2021
262021
Analogous detection of circulating tumor cells using the AccuCyte®—CyteFinder® system and ISET system in patients with locally advanced and metastatic …
EE van der Toom, VP Groot, SA Glavaris, G Gemenetzis, HJ Chalfin, ...
The Prostate 78 (4), 300-307, 2018
242018
Prostate cancer disseminated tumor cells are rarely detected in the bone marrow of patients with localized disease undergoing radical prostatectomy across multiple rare cell …
HJ Chalfin, SA Glavaris, PD Malihi, JM Sperger, MA Gorin, C Lu, ...
The Journal of urology 199 (6), 1494-1501, 2018
222018
Characterization of urothelial cancer circulating tumor cells with a novel selection-free method
HJ Chalfin, M Kates, EE van der Toom, S Glavaris, JE Verdone, NM Hahn, ...
Urology 115, 82-86, 2018
202018
Nucleolin staining may aid in the identification of circulating prostate cancer cells
HJ Chalfin, JE Verdone, EE van der Toom, S Glavaris, MA Gorin, ...
Clinical genitourinary cancer 15 (3), e477-e481, 2017
202017
Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer
AC Civelek, SA Niglio, AA Malayeri, J Lin, S Gurram, HJ Chalfin, ...
Urologic Oncology: Seminars and Original Investigations 39 (11), 787. e17 …, 2021
192021
Thrombosis risk in cancer patients receiving red blood cell transfusions
G Ramsey, PF Lindholm
Seminars in thrombosis and hemostasis 45 (06), 648-656, 2019
182019
Improving prostate cancer screening and diagnosis: health policy and biomarkers beyond PSA
HD Patel, HJ Chalfin, HB Carter
JAMA oncology 2 (7), 867-868, 2016
172016
Cabozantinib plus nivolumab phase I expansion study in patients with metastatic urothelial carcinoma refractory to immune checkpoint inhibitor therapy
DM Girardi, SA Niglio, A Mortazavi, R Nadal, P Lara, SK Pal, B Saraiya, ...
Clinical Cancer Research 28 (7), 1353-1362, 2022
152022
Robotic primary RPLND for stage I testicular cancer: a review of indications and outcomes
HJ Chalfin, W Ludwig, PM Pierorazio, ME Allaf
Current urology reports 17, 1-6, 2016
142016
系统目前无法执行此操作,请稍后再试。
文章 1–20